Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
21
02
2020
revised:
08
04
2020
accepted:
26
04
2020
pubmed:
10
5
2020
medline:
22
6
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis. HCV mono-infected and treatment naïve patients with non-severe fibrosis (Fibroscan Mean age was 54 ± 13 years, 31% were men and viral load was higher than 800.000 IU/mL in 70 of 112 patients (63%). Using Fibroscan Naïve patients with genotype 1b and non-severe fibrosis can achieve an SVR12 of 97% and an SVR24 of 95%. Then, these patients can be treated with grazoprevir-elbasvir for 8 weeks.
Sections du résumé
BACKGROUND
Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis.
METHODS
HCV mono-infected and treatment naïve patients with non-severe fibrosis (Fibroscan
FINDINGS
Mean age was 54 ± 13 years, 31% were men and viral load was higher than 800.000 IU/mL in 70 of 112 patients (63%). Using Fibroscan
INTERPRETATION
Naïve patients with genotype 1b and non-severe fibrosis can achieve an SVR12 of 97% and an SVR24 of 95%. Then, these patients can be treated with grazoprevir-elbasvir for 8 weeks.
Substances chimiques
Amides
0
Antiviral Agents
0
Benzofurans
0
Carbamates
0
Cyclopropanes
0
Imidazoles
0
Quinoxalines
0
Sulfonamides
0
Ribavirin
49717AWG6K
grazoprevir
4O2AB118LA
elbasvir
632L571YDK
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1853-1859Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of Hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176.
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the Hepatitis C virus infection. J Hepatol. 2014;61:S45-S57.
McHutchison J, Everson G, Gordon S, et al. for the PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.
Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic Hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med. 2015;163:1-13.
Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599-2607.
Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354-369.
Liu R, Curry S, McMonagle P, et al. Susceptibilities of genotype 1a, 1b, and 3 Hepatitis C virus variants to the NS5A inhibitor Elbasvir. Antimicrob Agents Chemother. 2015;59:6922-6929.
Morikawa K, Nakamura A, Shimazaki T, Sakamoto N. Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic Hepatitis C: current evidence. Drug Design, Development Therapy. 2018;12:2749-2756.
Zeuzem S, Serfaty L, Vierling J, et al. The safety and efficacy of elbasvir and grazoprevir in participants with Hepatitis C virus genotype 1b infection. J Gastroenterol. 2018;53:679-688.
Serfaty L, Zeuzem S, Vierling J, et al. High efficacy of the combination HCV regimen grazoprevir and elbasvir for 8 or 12 weeks with or without ribavirin in treatment-naive, noncirrhotic HCV GT1b-infected patients: an integrated analysis. AASLD Liver Meeting, San Francisco. Hepatology. 2015;62:701A.
Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic Hepatitis C. Hepatology. 2003;38:1449-1457.
Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic Hepatitis C. Gastroenterology. 2005;128:343-350.
Howe AY, Black S, Curry S, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with Hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59:1657-1665.
Liu R, Curry S, McMonagle P, et al. Susceptibilities of genotype 1a, 1b, and 3 Hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother. 2015;59:6922-6929.
Andre-Garnier E, Besse B, Rodallec A, et al. An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. PLoS ONE. 2017;12:e0179562.
Brown LD, Cai T, Dasgupta A. Interval estimation for a binomial proportion. Stat Sci. 2001;16:101-133.
Kowdley KV, Gordon SC, Reddy KR, et al.ION-3 Investigators. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New Engl J Med. 2014;370(20):1879-1888.
Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 Hepatitis C-infected patients. Hepatology. 2016;64:405-414.
Kowdley KV, Sundaram V, Jeon CY, et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection. Hepatology. 2017;65:1094-1103.
Buggisch P, Vermehren J, Mauss S, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic Hepatitis C. J Hepatol. 2018;68:663-671.
Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
Hepatitis C Guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection. Clin Infect Dis. 2018;67:1477-1492.
Welzel TM, Asselah T, Dumas EO, et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with Hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol. 2017;2:494-500.
Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 Hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:818-826.
Feld JJ, Jacobson IM, Hézode C, et al. ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599-2607.
Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113-122.
Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354-369.
Huang CF, Hung CH, Cheng PN, et al. An open-label, randomized, active-controlled trial of 8 versus 12 weeks of Elbasvir-grazoprevir for treatment-naive patients with chronic Hepatitis C Genotype 1b infection and mild fibrosis (EGALITE Study): impact of baseline viral loads and NS5A resistance-associated substitutions. J Infect Dis. 2019;220:557-566.
Aldunate F, Echeverría N, Chiodi D, et al. Pretreatment Hepatitis C virus NS5A/NS5B resistance-associated substitutions in genotype 1 Uruguayan infected patients. Dis Markers. 2018;2018:1-9.
Esposito I, Marciano S, Haddad L, et al. Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 Hepatitis C virus infection. Viruses. 2018;21:11.
Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in Hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646-654.
Kozuka R, Hai H, Motoyama H, et al. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. J Viral Hepat. 2018;25:535-542.
Wei L, Omata M, Lim YS, et al. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-resistance associated substitutions in HCV-infected patients in Mainland China. Antiviral Res. 2018;158:178-184.
Asselah T, Pol S, Hezode C, et al. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for Hepatitis C virus: genotype 4 infection: a randomized study. Liver Int. 2020;40(5):1042-1051.
Smolders EJ, Berden FA, de Kanter CT, Kievit W, Drenth JP, Burger DM. The majority of Hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions. United European Gastroenterol J. 2017;5:648-657.
Sicras Mainar A, Navarro Artieda R, Hernández I, Morillo R. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic Hepatitis C virus infection in Spain. Gastroenterol Hepatol. 2019;42:465-475.
Dictionnaire Vidal. https://www.vidal.fr.